(Q64216806)

English

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With DSXS in Patients With Atopic Dermatitis. (English)

0 references

0 references

0 references

United States of America

0 references

start time

28 August 2015

0 references

end time

22 February 2017

0 references

number of participants

24

0 references

clinical trial phase

phase II clinical trial

0 references

research site

Taro Pharmaceuticals (United States)

0 references

minimum age

2 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT02595008

0 references

(Q64216806)

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)